Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05235711 · ClinicalTrials.gov registry record

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
87
Enrollment target

NCT05235711: Completed study, sponsored by Mayo Clinic.

NCT05235711 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05235711 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
87 participants
Enrollment target

Study Summary

The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.

Primary Outcome

All-cause mortality

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2022-02-10
Est. Completion 2024-08-31
Mayo Clinic

2,844 total trials

What the finished NCT05235711 record still lists

NCT05235711 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT05235711 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05235711 about?

NCT05235711 is a clinical study titled "The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis". The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.

What is the current status of trial NCT05235711?

This trial is currently completed. The enrollment target is 87 participants. The study started on 2022-02-10. Estimated completion is 2024-08-31.

Who is sponsoring clinical trial NCT05235711?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05235711, the US trial registry maintained by the National Library of Medicine. NCT05235711 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.